Biotech · Private company · Cambridge, MA, US
Matrisome Bio, Inc.
Track this companyFree. Adds Matrisome Bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancerFiscal year 2026 · $1MNIH RePORTER 5R44CA298532-02 · fetched Nov 12, 2026
- Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancerFiscal year 2025 · $1.2MNIH RePORTER 1R44CA298532-01A1 · fetched Nov 12, 2026
- NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOCFiscal year 2025 · $354.5KNIH RePORTER 75N91025C00039-0-9999-1 · fetched Nov 12, 2026